Collegium Pharmaceutical, Inc. (COLL) Earns “Buy” Rating from Jefferies Group LLC
Collegium Pharmaceutical, Inc. (NASDAQ:COLL)‘s stock had its “buy” rating reaffirmed by stock analysts at Jefferies Group LLC in a research report issued on Friday. They presently have a $15.00 price objective on the specialty pharmaceutical company’s stock. Jefferies Group LLC’s price target suggests a potential upside of 31.81% from the stock’s previous close.
A number of other brokerages have also commented on COLL. Zacks Investment Research lowered shares of Collegium Pharmaceutical from a “hold” rating to a “sell” rating in a report on Tuesday, July 11th. ValuEngine upgraded shares of Collegium Pharmaceutical from a “strong sell” rating to a “sell” rating in a report on Thursday, June 22nd. Needham & Company LLC reiterated a “buy” rating and set a $25.00 price target on shares of Collegium Pharmaceutical in a report on Friday, June 9th. Janney Montgomery Scott reiterated a “buy” rating and set a $25.00 price target on shares of Collegium Pharmaceutical in a report on Monday, June 12th. Finally, HC Wainwright started coverage on shares of Collegium Pharmaceutical in a report on Monday, September 11th. They set a “buy” rating and a $21.00 price target on the stock. Two analysts have rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the stock. Collegium Pharmaceutical presently has a consensus rating of “Hold” and a consensus target price of $20.00.
Collegium Pharmaceutical (NASDAQ COLL) opened at 11.38 on Friday. The firm’s market cap is $336.46 million. The firm’s 50-day moving average price is $10.46 and its 200 day moving average price is $10.46. Collegium Pharmaceutical has a 12-month low of $9.27 and a 12-month high of $18.67.
Collegium Pharmaceutical (NASDAQ:COLL) last posted its earnings results on Wednesday, August 9th. The specialty pharmaceutical company reported ($0.72) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.81) by $0.09. The firm had revenue of $3.56 million for the quarter, compared to analysts’ expectations of $4.07 million. Collegium Pharmaceutical had a negative net margin of 1,319.39% and a negative return on equity of 93.73%. Analysts forecast that Collegium Pharmaceutical will post ($3.00) earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This story was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this story on another domain, it was copied illegally and reposted in violation of US and international copyright and trademark laws. The correct version of this story can be accessed at https://www.thecerbatgem.com/2017/10/06/collegium-pharmaceutical-inc-coll-earns-buy-rating-from-jefferies-group-llc.html.
Hedge funds have recently added to or reduced their stakes in the stock. American International Group Inc. lifted its holdings in Collegium Pharmaceutical by 27.8% in the first quarter. American International Group Inc. now owns 9,948 shares of the specialty pharmaceutical company’s stock valued at $100,000 after buying an additional 2,163 shares during the period. Nationwide Fund Advisors lifted its holdings in Collegium Pharmaceutical by 16.4% in the first quarter. Nationwide Fund Advisors now owns 10,087 shares of the specialty pharmaceutical company’s stock valued at $101,000 after buying an additional 1,422 shares during the period. Voya Investment Management LLC acquired a new position in Collegium Pharmaceutical in the second quarter valued at $125,000. Credit Suisse AG lifted its holdings in Collegium Pharmaceutical by 9.4% in the first quarter. Credit Suisse AG now owns 13,630 shares of the specialty pharmaceutical company’s stock valued at $137,000 after buying an additional 1,173 shares during the period. Finally, UBS Group AG lifted its holdings in Collegium Pharmaceutical by 283.2% in the first quarter. UBS Group AG now owns 13,767 shares of the specialty pharmaceutical company’s stock valued at $139,000 after buying an additional 10,174 shares during the period. Institutional investors and hedge funds own 83.04% of the company’s stock.
Collegium Pharmaceutical Company Profile
Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting.
Receive News & Stock Ratings for Collegium Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical Inc. and related stocks with our FREE daily email newsletter.